Quant Detect Corporation

Quantdetect, Inc. develops and provides diagnostic tools for tracking cancer-related genetic mutations. The company was founded on April 1, 2021, by Satoshi S. Nishizuka, M.D., Ph.D., stemming from technology and knowledge developed at Iwate Medical University Institute for Biomedical Sciences. Nishizuka serves as the CEO of the company.

The firm's core offerings are the OTS-Probes and the OTS-Assay, designed to identify and quantify recurrent gene mutations in cancer patients from blood samples. OTS, an abbreviation for Off-The-Shelf, refers to the ready-to-use nature of their digital PCR (dPCR) probes. This technology allows for the monitoring of circulating tumor DNA (ctDNA), which can help in evaluating treatment efficacy, predicting relapse earlier than standard methods, and confirming the absence of relapse. The OTS-Assay is a comprehensive process that first screens for gene mutations in resected tissue and then measures the same mutations in the blood. Quantdetect maintains a large library of pre-made dPCR probes, enabling rapid selection of a suitable probe for individual patients across various cancer types.

The company's business model focuses on supplying these highly sensitive diagnostic tools to cancer research institutions, pharmaceutical companies, and related organizations on a Research-Use-Only basis. It accepts blood or DNA samples to perform the OTS-Assay, examining how ctDNA levels reflect the tumor dynamics in a patient undergoing treatment. Headquartered in Tokyo, Japan, Quantdetect is a privately held, venture capital-backed company in the diagnostic equipment and HealthTech industries.

Keywords: cancer diagnostics, ctDNA, liquid biopsy, digital PCR, gene mutation analysis, oncology research, OTS-Probes, OTS-Assay, tumor monitoring, cancer treatment efficacy, personalized medicine, diagnostic tools, molecular diagnostics, life sciences, HealthTech, recurrent mutations, biomarker tracking, research use only